- Home
- STKS vs KZIA Comparison
STKS vs KZIA Comparison
Compare STKS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STKS | KZIA |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6M | 100.8M |
| IPO Year | 2011 | 2002 |
Fundamental Metrics
Financial Performance| Metric | STKS | KZIA |
|---|---|---|
| Price | $1.74 | $9.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.70 | ★ $17.67 |
| AVG Volume (30 Days) | 46.4K | ★ 139.4K |
| Earning Date | 05-06-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.66 | $2.86 |
| 52 Week High | $5.19 | $17.40 |
Technical Indicators
Market Signals| Indicator | STKS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 63.48 |
| Support Level | $1.67 | $5.64 |
| Resistance Level | $2.03 | $10.49 |
| Average True Range (ATR) | 0.12 | 0.84 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 21.62 | 72.26 |
Price Performance
Historical ComparisonAbout STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.